利拉鲁肽对 2 型糖尿病患者肾功能的影响：一项随机对照研究的荟萃分析。

The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.

机构信息

Department of Endocrinology, The Quzhou Affiliated of Wenzhou Medical University, Quzhou People's Hospital, Zhejiang, P.R. China.

出版信息

Afr Health Sci. 2022 Sep;22(3):267-274. doi: 10.4314/ahs.v22i3.28.

INTRODUCTION

The efficacy of liraglutide on renal function in type 2 diabetes remains controversial. We conduct a systematic review and meta-analysis to explore the influence of liraglutide versus placebo on renal function in type 2 diabetes.

METHODS

We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes. This meta-analysis is performed using the random-effect model.

RESULTS

Seven RCTs are included in the meta-analysis. Overall, compared with control group in type 2 diabetes, liraglutide treatment shows no obvious effect on GFR (SMD=0.02; 95% CI=-0.43 to 0.47; P=0.94), RBF (SMD=-0.28; 95% CI=-0.80 to 0.24; P=0.29) or death (RR=1.93; 95% CI=0.71 to 5.21; P=0.20), but is associated with significantly decreased ACR (SMD=-0.82; 95% CI=-1.39 to -0.26; P=0.004) and systolic blood pressure (MD=-9.60; 95% CI=-17.46 to -1.73; P=0.02), as well as increased heart rate (MD=5.39; 95% CI=3.26 to 7.52; P<0.00001).

CONCLUSIONS

Liraglutide treatment may provide some benefits for protecting renal function in type 2 diabetes.

简介

利拉鲁肽对 2 型糖尿病患者肾功能的疗效仍存在争议。我们进行了一项系统评价和荟萃分析，以探讨利拉鲁肽与安慰剂相比对 2 型糖尿病患者肾功能的影响。

方法

我们通过检索 PubMed、EMbase、Web of Science、EBSCO 和 Cochrane 图书馆数据库，检索了截至 2020 年 3 月评估利拉鲁肽与安慰剂相比对 2 型糖尿病患者肾功能影响的随机对照试验（RCT）。本荟萃分析采用随机效应模型进行。

结果

共有 7 项 RCT 纳入荟萃分析。总体而言，与 2 型糖尿病对照组相比，利拉鲁肽治疗对 GFR（SMD=0.02；95%CI=-0.43 至 0.47；P=0.94）、RBF（SMD=-0.28；95%CI=-0.80 至 0.24；P=0.29）或死亡率（RR=1.93；95%CI=0.71 至 5.21；P=0.20）无明显影响，但与 ACR（SMD=-0.82；95%CI=-1.39 至 -0.26；P=0.004）和收缩压（MD=-9.60；95%CI=-17.46 至 -1.73；P=0.02）的显著降低以及心率（MD=5.39；95%CI=3.26 至 7.52；P<0.00001）的显著增加相关。